iRadimed/$IRMD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About iRadimed

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

Ticker

$IRMD
Primary listing

Industry

Health Care Equipment & Supplies

Employees

160

ISIN

US46266A1097

iRadimed Metrics

BasicAdvanced
$768M
38.97
$1.55
0.92
$0.64
1.13%

What the Analysts think about iRadimed

Analyst ratings (Buy, Hold, Sell) for iRadimed stock.

Bulls say / Bears say

Iradimed reported its 14th consecutive quarter of record-breaking revenues, with Q4 2024 revenue reaching $19.2–$19.4 million, indicating consistent growth and market share gains. (stocktitan.net)
The company increased its quarterly dividend to $0.17 per share, reflecting confidence in its financial health and commitment to returning value to shareholders. (marketbeat.com)
Analysts at Roth Mkm raised their price target for Iradimed to $72.00, up from $60.00, indicating strong growth prospects and positive market sentiment. (etfdailynews.com)
Iradimed's Q4 2024 earnings per share of $0.40 missed analysts' consensus estimates of $0.45, potentially raising concerns about profitability. (etfdailynews.com)
Following the earnings miss, StockNews.com downgraded Iradimed's rating from 'strong-buy' to 'buy,' suggesting a tempered outlook on the stock. (etfdailynews.com)
The stock experienced a gap down in trading after the earnings announcement, indicating negative investor reaction to the financial results. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.

iRadimed Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

iRadimed Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IRMD

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs